Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics
- PMID: 34007978
- PMCID: PMC8240848
- DOI: 10.1093/cid/ciab408
Population-Based Estimates of Post-acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (PASC) Prevalence and Characteristics
Abstract
Background: Emerging evidence suggests many people have persistent symptoms after acute coronavirus disease 2019 (COVID-19) illness. Our objective was to estimate the prevalence and correlates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC).
Methods: We used a population-based probability survey of adults with COVID-19 in Michigan. Living noninstitutionalized adults aged ≥18 in the Michigan Disease Surveillance System with COVID-19 onset through mid-April 2020 were eligible for selection (N = 28 000). Among 2000 selected, 629 completed the survey between June-December 2020. We estimated PASC prevalence, defined as persistent symptoms ≥30 (30-day COVID-19) or ≥60 (60-day COVID-19) days post-COVID-19 onset, overall and by sociodemographic and clinical factors. We used modified Poisson regression to produce adjusted prevalence ratios (aPRs) for potential risk factors.
Results: The analytic sample (n = 593) was predominantly female (56.1%), aged ≥45 years (68.2%), and non-Hispanic White (46.3%) or Black (34.8%). Thirty- and 60-day COVID-19 were highly prevalent (52.5% and 35.0%), even among nonhospitalized respondents (43.7% and 26.9%) and respondents reporting mild symptoms (29.2% and 24.5%). Respondents reporting very severe (vs mild) symptoms had 2.25 times higher prevalence of 30-day COVID-19 (aPR, 2.25; 95% CI, 1.46-3.46) and 1.71 times higher prevalence of 60-day COVID-19 (aPR, 1.71; 95% CI: 1.02-2.88). Hospitalized (vs nonhospitalized) respondents had ~40% higher prevalence of both 30-day (aPR, 1.37; 95% CI: 1.12-1.69) and 60-day (aPR, 1.40; 95% CI: 1.02-1.93) COVID-19.
Conclusions: PASC is highly prevalent among cases reporting severe initial symptoms and, to a lesser extent, cases reporting mild and moderate symptoms.
Keywords: COVID-19; PASC; probability survey.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Similar articles
-
Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy.Obstet Gynecol. 2024 Sep 1;144(3):411-420. doi: 10.1097/AOG.0000000000005670. Epub 2024 Jul 11. Obstet Gynecol. 2024. PMID: 38991216 Free PMC article.
-
A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.BMC Infect Dis. 2021 Jul 13;21(1):677. doi: 10.1186/s12879-021-06359-2. BMC Infect Dis. 2021. PMID: 34256735 Free PMC article.
-
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection.Neurol Neuroimmunol Neuroinflamm. 2022 Mar 7;9(3):e1151. doi: 10.1212/NXI.0000000000001151. Print 2022 May. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35256481 Free PMC article.
-
Neurological post-acute sequelae of SARS-CoV-2 infection.Psychiatry Clin Neurosci. 2023 Feb;77(2):72-83. doi: 10.1111/pcn.13481. Epub 2022 Oct 17. Psychiatry Clin Neurosci. 2023. PMID: 36148558 Free PMC article. Review.
-
The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection.Curr Neurol Neurosci Rep. 2021 Jun 28;21(9):44. doi: 10.1007/s11910-021-01130-1. Curr Neurol Neurosci Rep. 2021. PMID: 34181102 Free PMC article. Review.
Cited by
-
Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence.Front Med (Lausanne). 2022 Sep 23;9:1003103. doi: 10.3389/fmed.2022.1003103. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36213654 Free PMC article.
-
Associations Between Acute COVID-19 Symptom Profiles and Long COVID Prevalence: Population-Based Cross-Sectional Study.JMIR Public Health Surveill. 2024 Oct 1;10:e55697. doi: 10.2196/55697. JMIR Public Health Surveill. 2024. PMID: 39352725 Free PMC article.
-
Factors Associated With Long COVID Symptoms in an Online Cohort Study.Open Forum Infect Dis. 2023 Feb 1;10(2):ofad047. doi: 10.1093/ofid/ofad047. eCollection 2023 Feb. Open Forum Infect Dis. 2023. PMID: 36846611 Free PMC article.
-
A Tale of 3 Pandemics: Severe Acute Respiratory Syndrome Coronavirus 2, Hepatitis C Virus, and Human Immunodeficiency Virus in an Urban Emergency Department in Baltimore, Maryland.Open Forum Infect Dis. 2022 Mar 16;9(5):ofac130. doi: 10.1093/ofid/ofac130. eCollection 2022 May. Open Forum Infect Dis. 2022. PMID: 35392453 Free PMC article.
-
SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.Science. 2022 Jan 21;375(6578):331-336. doi: 10.1126/science.abm0620. Epub 2021 Nov 4. Science. 2022. PMID: 34735261 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous